Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(8): e105828, 2014.
Article in English | MEDLINE | ID: mdl-25148251

ABSTRACT

The development of modular constructs that include antigenic regions targeted by protective immune responses is an attractive approach for subunit vaccine development. However, a main concern of using these vaccine platforms is how to preserve the antigenic identity of conformational B cell epitopes. In the present study we evaluated naturally acquired antibody responses to a chimeric protein engineered to contain a previously defined immunodominant domain of the Plasmodium vivax reticulocyte binding protein-1 located between amino acid positions K435-I777. The construct also includes three regions of the cognate protein (F571-D587, I1745-S1786 and L2235-E2263) predicted to contain MHC class II promiscuous T cell epitopes. Plasma samples from 253 naturally exposed individuals were tested against this chimeric protein named PvRMC-RBP1 and a control protein that includes the native sequence PvRBP123-751 in comparative experiments to study the frequency of total IgG and IgG subclass reactivity. HLA-DRB1 and HLA-DQB1 allelic groups were typed by PCR-SSO to evaluate the association between major HLA class II alleles and antibody responses. We found IgG antibodies that recognized the chimeric PvRMC-RBP1 and the PvRBP123-751 in 47.1% and 60% of the studied population, respectively. Moreover, the reactivity index against both proteins were comparable and associated with time of exposure (p<0.0001) and number of previous malaria episodes (p<0.005). IgG subclass profile showed a predominance of cytophilic IgG1 over other subclasses against both proteins tested. Collectively these studies suggest that the chimeric PvRMC-RBP1 protein retained antigenic determinants in the PvRBP1435-777 native sequence. Although 52.9% of the population did not present detectable titers of antibodies to PvRMC-RBP1, genetic restriction to this chimeric protein does not seem to occur, since no association was observed between the HLA-DRB1* or HLA-DQB1* alleles and the antibody responses. This experimental evidence strongly suggests that the identity of the conformational B cell epitopes is preserved in the chimeric protein.


Subject(s)
HLA-DQ beta-Chains/immunology , HLA-DRB1 Chains/immunology , Immunoglobulin G/blood , Malaria Vaccines/genetics , Malaria, Vivax/immunology , Membrane Proteins/immunology , Protozoan Proteins/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Animals , Brazil , Case-Control Studies , Child , Epitopes, T-Lymphocyte/immunology , Female , HLA-DQ beta-Chains/genetics , HLA-DRB1 Chains/genetics , Humans , Malaria Vaccines/immunology , Malaria, Vivax/genetics , Male , Membrane Proteins/genetics , Mice, Inbred BALB C , Middle Aged , Molecular Sequence Data , Plasmodium vivax/pathogenicity , Protozoan Proteins/genetics , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...